IMU Discussion

[TechGirl]

Really looking forward to listening to this today at 10am

Imugene's Science Series will feature the inventors behind its technologies, key opinion leaders in the field of immuno-oncology and treating oncologists on the clinical trials.

This session will see Imugene's B-cell immuno-therapy PD1-Vaxx covered in greater detail, with its inventor Professor Pravin Kaumaya and Imugene's Senior Director of Clinical Science Dr Nimali Withana.
Time

Feb 23, 2022 10:00 AM in Canberra, Melbourne, Sydney

Link to registration

Welcome! You are invited to join a webinar: Imugene Science Series – PD1-Vaxx. After registering, you will receive a confirmation email about joining the webinar.

Imugene's Science Series will feature the inventors behind its technologies, key opinion leaders in the field of immuno-oncology and treating oncologists on the clinical trials. This session will see Imugene's B-cell immuno-therapy PD1-Vaxx covered in greater detail, with its inventor...

us02web.zoom.us

 

[Hittman]

I had a nibble at them today.

 

[Fact Finder]

Really looking forward to listening to this today at 10am

Imugene's Science Series will feature the inventors behind its technologies, key opinion leaders in the field of immuno-oncology and treating oncologists on the clinical trials.

This session will see Imugene's B-cell immuno-therapy PD1-Vaxx covered in greater detail, with its inventor Professor Pravin Kaumaya and Imugene's Senior Director of Clinical Science Dr Nimali Withana.
Time

Feb 23, 2022 10:00 AM in Canberra, Melbourne, Sydney

Link to registration

Welcome! You are invited to join a webinar: Imugene Science Series – PD1-Vaxx. After registering, you will receive a confirmation email about joining the webinar.

Imugene's Science Series will feature the inventors behind its technologies, key opinion leaders in the field of immuno-oncology and treating oncologists on the clinical trials. This session will see Imugene's B-cell immuno-therapy PD1-Vaxx covered in greater detail, with its inventor...

us02web.zoom.us

I absolutely love to hear incredibly intelligent dedicated individuals speak to their passion regardless of what area of science it is they are passionate about I find it inspirational. I have just watched this presentation and feel ten years younger as a result. To be as engaged and passionate as Professor Pravin Kaumaya is after 30 years of research is astonishing. Dr. Nimali Withana would be an incredible mentor. So full of hope and passion.

My opinion only DYOR
FF

AKIDA BALLISTA

 

[jeff2151]

As with BRN, I don't pretend to have a full understanding of the science being used by Imugene, but my knowledge (in both companies) has greatly increased since I became interested in their work - as a result of my own research, the company publications and webcasts, and the research done by the many knowledgeable posters here and elsewhere.
As you listen to a talk like today's, one cannot help but be impressed by the depth of knowledge and the willingness to share with others in a collaborative way to reach a successful outcome.
Nor can you fail to be drawn in by the genuine enthusiasm and dedication shown by the two companies' employees - qualities that seem to increase the closer you get to the top.
Both companies maintain their clients/patients as their top priority, refusing to be distracted by petty side-issues like the current share price. As Leslie Chong has often said, if they get the science right, the share price will eventually follow.
Like FF, I love listening to these scientists. They ooze intellect. But as well as that, they are genuine, wonderful people who inspire such confidence in the research for which they are responsible.
The icing on the cake is the way these companies care about their shareholders.
After a meeting like today's, I'm always left with an awe-inspired desire to work out how I can find more money to invest! Today I'm tempted to sell some BRN to buy more IMU. But then I listen to something from BRN and I'm tempted to sell some IMU to buy more BRN. lol What a delightful position to be in, as an investor.
Jeff

 

[Fact Finder]

As with BRN, I don't pretend to have a full understanding of the science being used by Imugene, but my knowledge (in both companies) has greatly increased since I became interested in their work - as a result of my own research, the company publications and webcasts, and the research done by the many knowledgeable posters here and elsewhere.
As you listen to a talk like today's, one cannot help but be impressed by the depth of knowledge and the willingness to share with others in a collaborative way to reach a successful outcome.
Nor can you fail to be drawn in by the genuine enthusiasm and dedication shown by the two companies' employees - qualities that seem to increase the closer you get to the top.
Both companies maintain their clients/patients as their top priority, refusing to be distracted by petty side-issues like the current share price. As Leslie Chong has often said, if they get the science right, the share price will eventually follow.
Like FF, I love listening to these scientists. They ooze intellect. But as well as that, they are genuine, wonderful people who inspire such confidence in the research for which they are responsible.
The icing on the cake is the way these companies care about their shareholders.
After a meeting like today's, I'm always left with an awe-inspired desire to work out how I can find more money to invest! Today I'm tempted to sell some BRN to buy more IMU. But then I listen to something from BRN and I'm tempted to sell some IMU to buy more BRN. lol What a delightful position to be in, as an investor.
Jeff

I thought I was the only one who lived with this conflict on a daily basis which in the end means I sell neither. LOL FF.

 

[Hittman]

I thought I was the only one who lived with this conflict on a daily basis which in the end means I sell neither. LOL FF.

I'm happy with my BRN exposure so slowly building IMU. .

 

[Solotrader]

Yes , when you have some funds to top up the quandary is ....BRN....or ...IMU ? Yesterday it was IMU and I got in the queue @ 24.5 This morning it dropped to 24.5 and ate up almost all of the order in front of me before it recovered. I will count the cost of picking the bottom ....but not quite closing it. Follow the science !

 

[Mannic]

 

[Mannic]

IMU is top 37 shares on the ASX shorted.
Hope it follows BRN and burns those

 

[Slymeat]

Celularity receiving orphan drug designation by FDA

https://celularity.com/celularity-r...positive-gastric-and-gastroesophageal-juncti/

Should bode well for Imugene considering there partnership in this area.

https://celularity.com/imugene-and-...ombination-for-the-treatment-of-solid-tumors/

Orphan drug designation for Celularity for tumors exhibiting the CD-19 marker and hey, here’s Imugene with a mechanism to mark solid tumours with said CD-19 marker, and an established exclusive partnership with Celularity.

Sounds like a marriag made in a Petri dish.

Should be something positive for this day that has red written all over it.

 

[Iseki]

An orphan drug is a pharmaceutical agent developed to treat medical conditions which, because they are so rare, would not be profitable to produce without government assistance.

 

[Slymeat]

An orphan drug is a pharmaceutical agent developed to treat medical conditions which, because they are so rare, would not be profitable to produce without government assistance.

Only 2.3% of all deaths from cancer. Probably not worth worrying about then hey!

 

[Iseki]

Only 2.3% of all deaths from cancer. Probably not worth worrying about then hey!

Hey, I'd like to cure cancer like everyone.

How do you understand the exclusivity of the agreement between the two companies will work?

 

[Slymeat]

Hey, I'd like to cure cancer like everyone.
How do you understand the exclusivity of the agreement between the two companies will work?

I was just joining the dots and sharing in case others didn’t notice the significance of two articles posted a few weeks apart.

The details of exclusivity are in the link included above, titled “Imugene and Celularity Announce an Exclusive Strategic Partnership to Develop a Novel Oncolytic Virus – Allogeneic CAR T-Cell Immunotherapy Combination for the Treatment of Solid Tumors”.

As I understand matters, the exclusivity is for the CF33-CD19 oncolytic virus for which Imugene has an exclusive license, in combination with the allogeneic nature of Celularity’s CAR-T Immunotherapy.

Other CAR-T therapies already are TGA approved, and Imugene has trials with these also, but these have to be cultured from the recipient’s own T cells. That path isn’t available for patients with a compromised immune system.

 

[JohnMaz]

Sadly VUL is up the top :-( as well. They could do with moving over here from HC, as it's a toxic forum for VUL over there at the moment.

 

[Terroni2105]

After the positive Ann this morning there is 21million on the buy side and 11million on the sell side, lets hope SP pushes up and finds a higher and solid base

 

[Iseki]

After the positive Ann this morning there is 21million on the buy side and 11million on the sell side, lets hope SP pushes up and finds a higher and solid base

Hope so.
Is this a new trial or inclusion of keytruda into
ClinicalTrials.gov Identifier: NCT02795988

ClinicalTrials.gov

clinicaltrials.gov

 

[Fact Finder]

ASX Announcement
IMUGENE RECEIVES ETHICS APPROVAL TO START PHASE I CLINICAL TRIAL OF
NEW CANCER ONCOLYTIC VIROTHERAPY VAXINIA IN USA
_______________________________________________________________________________________
SYDNEY, Australia, 23 March 2022: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology
company, today announced it has received Western Institutional Review Board (WIRB) approval to
commence a Phase I clinical trial of its oncolytic virotherapy candidate, VAXINIA (CF33-hNIS,
HOV2) in multiple solid tumours in patients.
The US component of the Phase I trial will be conducted under the Food and Drug Administration
(FDA) investigational new drug (IND) process following FDA IND clearance in December 2021.
Site activation and patient recruitment will proceed immediately.
The first hospital in the USA to receive ethics approval is the City of Hope®, a world-renowned
independent cancer research and treatment center near Los Angeles. Additional clinical sites will
be opened across the USA in 2022.
The clinical trial is titled “A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA
(CF33- hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination
with Pembrolizumab in Adult Patients with Metastatic or Advanced Solid Tumours (MAST)”. The
trial is anticipated to run for 24 months and is funded from existing budgets and resources.
The Principal Investigator leading the trial at City of Hope is Dr Daneng Li MD, an assistant
professor in the Department of Medical Oncology & Therapeutics Research at City of Hope,
specializing in treating gastrointestinal cancers. Dr Li currently leads the liver tumours program
and is also the co-director of the Neuroendocrine Tumour Program at City of Hope.
This is an open-label, dose-escalation, multi-centre phase I study evaluating the safety of CF33-
hNIS (hNIS – human sodium iodide symporter) administered via two routes of administration,
intratumoural (IT) or intravenous (IV), either as a monotherapy or in combination with
pembrolizumab administered intravenously in patients with metastatic or advanced solid tumours.
The trial will involve a dose escalation, before the trial expands to up to 10 patients at the final
monotherapy and combination dose. CF33-hNIS is a chimeric vaccinia poxvirus from the lab of

 

[Mannic]

Finally the SP has gone up with a positive announcement

 

[TechGirl]

New Article

Fighting Back: 3 ASX cancer stocks giving hope in a leading cause of death​

Fighting Back: 3 ASX cancer stocks giving hope in a leading cause of death - Stockhead

According to the World Health Organisation Cancer is a leading cause of death worldwide, but these three ASX cancer stocks are giving hope.

stockhead.com.au

Pic:Getty Images

Fighting Back: 3 ASX cancer stocks giving hope in a leading cause of death​

Health & Biotech
7 hours ago | Nadine McGrath

SHARE​

• 
• 
• 
• 

• Prescient Thereapeutics gives hope with its personalised Car-T cell therapy
• Imugene working to activate the immune systems of cancer suffers to fight disease
• Rhythm Bioscience revolutionising the detection of bowel cancer

According to the World Health Organisation, cancer accounted for nearly 10 million deaths in 2020, or nearly one in six deaths.
Here are 3 small and mid-cap ASX cancer stocks working for better treatments and early detection of cancer.

1.Prescient Therapeutics leaders in CAR-T cell therapy​

Clinical stage oncology company Prescient Therapeutics (ASXTX) develops novel, personalised therapies for a range of cancers.
Prescient’s universal CAR-T and targeted therapies seek to improve patient outcomes, whilst also offering new tools for clinicians in combating cancer.
Prescient Therapeutics is working to rapidly expand the application of universal CAR-T therapies, capable of addressing all cancer types, including solid tumours.
The company recently expanded patient recruitment for a trial into lead drug candidate, PTX-100, in the treatment of patients with T-cell lymphomas.
The decision to expand the trial followed excellent safety data and promising preliminary evidence of clinical efficiency.
The company has a market cap of ~$84.5 million. Its share price has risen 30% in the past year to 13 cents.

2.Imugene therapies aim to identity and eradicate tumors​

Imugene (ASX:IMU) is a clinical stage immuno-oncology company developing new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors.
The company has novel technology platforms delivering immunotherapy including oncolytic virotherapies, onCARlytics in celluar therapy and B-Cell activating immunotherapies.
Imugene has several clinical trials underway, including a collaboration with global giants Pfizer and Merck for the Phase 2 trial of HER-Vaxx.
HER-Vaxx is a B-cell immuno-therapy to treat tumours over-expressing the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.
Imugene is headed by Australia biotech veteran Paul Hopper and has a market cap of $1.34 billion. Its share price is up ~18% in the past year to 22 cents.

Rhythm Biosciences develops blood test to detect bowel cancer​

Rhythm Biosciences (ASX:RHY) is working to replace invasive bowel cancer screening with a simple blood test.
Rhythm’s recently announced promising results from a clinical trial of its blood test product ColoSTAT exhibited very high accuracy for the detection of colorectal cancer.
The trial showed statistically significant performance, recording 81% sensitivity, and a specificity of 91%.
ColoSTAT was also shown to be 35% more accurate than the market standard Faecal Immunochemical Test (FIT) for detecting cancer and advanced adenomas.
ColoStat has a market cap of ~$300 million. Its share price is up ~25.% in the past year to $1.40.